Literature DB >> 1596145

Surgical treatment of tricuspid regurgitation.

J H Kay1.   

Abstract

The technique of tricuspid valve repair for tricuspid regurgitation has been used effectively since 1961. The first publication of the method appeared in 1965 in the Annals of Surgery. The procedure has changed little since that time and has afforded excellent long-term results. The procedure consists of excluding the annulus of the posterior leaflet of the tricuspid valve. The technique is simple, fast, hemodynamically effective, and durable. It carries no risk of heart block because the posterior leaflet annulus is far from the conduction system. An inferior caval snare may produce inadequate drainage with resulting increased back pressure on the liver leading to hepatocellular necrosis and lethal postoperative liver dysfunction in 3 to 5 days. Therefore, an inferior caval snare is never used when repairing or replacing the tricuspid valve for acquired or rheumatic heart disease. Morbidity and mortality are also decreased by restricting fluids in the postoperative period.

Entities:  

Mesh:

Year:  1992        PMID: 1596145     DOI: 10.1016/0003-4975(92)90411-v

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Prediction of postoperative hepatic dysfunction after cardiac surgery in patients with chronic congestive heart failure.

Authors:  Hiroyuki Nishi; Toshiki Takahashi; Hajime Ichikawa; Goro Matsumiya; Hikaru Matsuda; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-07-14

Review 2.  Transcatheter therapies for severe tricuspid regurgitation. Quo vadis?

Authors:  Brunilda Alushi; Kourosh Vathie; Holger Thiele; Alexander Lauten
Journal:  Herz       Date:  2020-05-28       Impact factor: 1.443

Review 3.  Advances in transcatheter mitral and tricuspid therapies.

Authors:  Pavel Overtchouk; Nicolo Piazza; Juan Granada; Osama Soliman; Bernard Prendergast; Thomas Modine
Journal:  BMC Cardiovasc Disord       Date:  2020-01-07       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.